Literature DB >> 6861805

First results of immunotherapy with immunoglobulin G in multiple sclerosis patients.

E Schuller, A Govaerts.   

Abstract

31 patients with multiple sclerosis were treated for an mean period of 4 years with high doses of human immunoglobulin. Overall, one third improved, one third showed no change and one third deteriorated. The effect of treatment was not related to any clinical or biological variable except perhaps the immunogenetic profile (HLA). The potential role of this symptomatic treatment is discussed.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6861805     DOI: 10.1159/000115560

Source DB:  PubMed          Journal:  Eur Neurol        ISSN: 0014-3022            Impact factor:   1.710


  12 in total

Review 1.  Intravenous immunoglobulins as therapeutic option in the treatment of multiple sclerosis.

Authors:  Ales Dudesek; Uwe K Zettl
Journal:  J Neurol       Date:  2006-09       Impact factor: 4.849

Review 2.  Basic principles of intravenous immunoglobulin (IVIg) treatment.

Authors:  Martin Stangel; Refik Pul
Journal:  J Neurol       Date:  2006-09       Impact factor: 4.849

Review 3.  Intravenous immunoglobulin (IVIG) for the therapy of autoimmune disorders.

Authors:  S A Schwartz
Journal:  J Clin Immunol       Date:  1990-03       Impact factor: 8.317

4.  Intravenous immune globulin impairs anti-bacterial defences of a cyclophosphamide-treated host.

Authors:  A S Cross; G Siegel; W R Byrne; M Trautmann; D S Finbloom
Journal:  Clin Exp Immunol       Date:  1989-05       Impact factor: 4.330

Review 5.  Treatment of multiple sclerosis with IVIg: potential effects and methodology of clinical trials.

Authors:  P S Sørensen
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-11       Impact factor: 10.154

Review 6.  In vitro effects of polyvalent immunoglobulin for intravenous use.

Authors:  I N van Schaik; M Vermeulen; A Brand
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-11       Impact factor: 10.154

Review 7.  Mechanisms of action of intravenous immunoglobulin in inflammatory muscle disease.

Authors:  Adam Quick; Rup Tandan
Journal:  Curr Rheumatol Rep       Date:  2011-06       Impact factor: 4.592

Review 8.  Promotion of remyelination by polyclonal immunoglobulin in Theiler's virus-induced demyelination and in multiple sclerosis.

Authors:  B G van Engelen; D J Miller; K D Pavelko; O R Hommes; M Rodriguez
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-11       Impact factor: 10.154

9.  Current proposed mechanisms of action of intravenous immunoglobulins in inflammatory neuropathies.

Authors:  Saiju Jacob; Yusuf A Rajabally
Journal:  Curr Neuropharmacol       Date:  2009-12       Impact factor: 7.363

Review 10.  Immunoglobulin therapy in neurologic diseases.

Authors:  P Berlit
Journal:  Klin Wochenschr       Date:  1989-10-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.